Effect of Herbal Medicine Formulation (Compound Honey Syrup) on Quality of Life in Patients With COPD: A Randomized Clinical Trial.

Q3 Medicine Tanaffos Pub Date : 2022-03-01
Zohreh Poursaleh, Rasool Choopani, Ensieh Vahedi, Abbas Fadaei Khedmat, Ali Ghazvini, Mahmood Salesi, Mostafa Ghanei
{"title":"Effect of Herbal Medicine Formulation (Compound Honey Syrup) on Quality of Life in Patients With COPD: A Randomized Clinical Trial.","authors":"Zohreh Poursaleh,&nbsp;Rasool Choopani,&nbsp;Ensieh Vahedi,&nbsp;Abbas Fadaei Khedmat,&nbsp;Ali Ghazvini,&nbsp;Mahmood Salesi,&nbsp;Mostafa Ghanei","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) as one of the health-threatening problems imposes many economic costs on health systems. Today, there is a greater tendency to use complementary and alternative therapies in the treatment of diseases. This study aimed to evaluate the efficacy of a Persian herbal formulation in patients with COPD.</p><p><strong>Materials and methods: </strong>This randomized clinical trial was conducted on 76 patients with mild-severe COPD assigned to 2 groups (in each group n=38) for 8 weeks. The interventional group received Compound Honey Syrup (CHS), consisting of combination of honey and extracts of five medicinal plants (i.e., ginger, cinnamon, saffron, cardamom, and galangal) and the control group received a placebo. The COPD Assessment Test (CAT), St George's Respiratory Questionnaire (SGRQ), and lung function test were used before and after.</p><p><strong>Results: </strong>Seventy-six patients, 88.6% male and 55.7% under 60 years of age, completed the course of treatment. At the end of the study, the overall score of the CAT questionnaire was significantly different between the first and fourth week (P=0.029). Meanwhile the findings of SGRQ questionnaire were significantly different between the interventional and control groups at other times (P=0.001). FEV1 and FEV1/FVC were found to be significantly different between two groups in weeks 4 and 8 (P <0.05). At the end of the study, no side effects of CHS were reported.</p><p><strong>Conclusion: </strong>Based on the data presented herein, CHS could be effective as a complementary and safe drug in increasing the quality of life of with COPD.</p>","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/fc/Tanaffos-21-336.PMC10073945.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tanaffos","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Chronic obstructive pulmonary disease (COPD) as one of the health-threatening problems imposes many economic costs on health systems. Today, there is a greater tendency to use complementary and alternative therapies in the treatment of diseases. This study aimed to evaluate the efficacy of a Persian herbal formulation in patients with COPD.

Materials and methods: This randomized clinical trial was conducted on 76 patients with mild-severe COPD assigned to 2 groups (in each group n=38) for 8 weeks. The interventional group received Compound Honey Syrup (CHS), consisting of combination of honey and extracts of five medicinal plants (i.e., ginger, cinnamon, saffron, cardamom, and galangal) and the control group received a placebo. The COPD Assessment Test (CAT), St George's Respiratory Questionnaire (SGRQ), and lung function test were used before and after.

Results: Seventy-six patients, 88.6% male and 55.7% under 60 years of age, completed the course of treatment. At the end of the study, the overall score of the CAT questionnaire was significantly different between the first and fourth week (P=0.029). Meanwhile the findings of SGRQ questionnaire were significantly different between the interventional and control groups at other times (P=0.001). FEV1 and FEV1/FVC were found to be significantly different between two groups in weeks 4 and 8 (P <0.05). At the end of the study, no side effects of CHS were reported.

Conclusion: Based on the data presented herein, CHS could be effective as a complementary and safe drug in increasing the quality of life of with COPD.

Abstract Image

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中药制剂(复方蜂蜜糖浆)对慢性阻塞性肺病患者生活质量的影响:一项随机临床试验
背景:慢性阻塞性肺疾病(COPD)作为威胁健康的问题之一,给卫生系统带来了许多经济成本。今天,在疾病治疗中使用补充和替代疗法的趋势更大。本研究旨在评估波斯草药制剂对慢性阻塞性肺病患者的疗效。材料与方法:将76例中重度COPD患者随机分为两组(每组38例),为期8周。干预组服用复方蜂蜜糖浆(CHS),由蜂蜜和五种药用植物(生姜、肉桂、藏红花、豆蔻、高良姜)的提取物混合而成,对照组服用安慰剂。前后分别采用慢阻肺评估试验(CAT)、圣乔治呼吸问卷(SGRQ)和肺功能测试。结果:76例患者完成疗程,其中男性占88.6%,60岁以下占55.7%。研究结束时,第1周与第4周CAT问卷总分比较,差异有统计学意义(P=0.029)。同时,干预组与对照组在其他时间的SGRQ问卷调查结果差异有统计学意义(P=0.001)。两组FEV1和FEV1/FVC在第4周和第8周差异有统计学意义(P)。结论:基于本研究数据,CHS可作为一种安全有效的补充药物,提高COPD患者的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Tanaffos
Tanaffos Medicine-Critical Care and Intensive Care Medicine
CiteScore
1.10
自引率
0.00%
发文量
0
期刊最新文献
Oncologic Emergencies in Lung Cancer Patients and the Effects of SARS-COV2 Pandemic. Relationship between Underlying Diseases with Morbidity and Mortality in Patients with COVID-19. Status of Inflammatory and Coagulation Factors in COVID-19 and Its Relation with the Disease Severity. Tracheal Lobular Capillary Hemangioma: A Rare Localization. Tracheal Small Cell Carcinoma in a 52-year-old Male: A Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1